Latest News
Acrivon Therapeutics, Inc.
- Acrivon unveils CDK11 inhibitor ACR-7280 for acute myeloid leukemia
- Acrivon advances CDK11 inhibitor for AML, targets 2027 IND filing By Investing.com
- Acrivon advances CDK11 inhibitor for AML, targets 2027 IND filing By Investing.com
- Acrivon Therapeutics, Inc. Advances Acr-7280, an Oral Cdk11 Inhibitor, Toward Investigational New Drug Filing
- Acrivon Advances ACR-7280, an Optimized, AP3-Enabled,
- Acrivon Therapeutics (ACRV) Grinds Higher: Micro-Cap Biotech Ticks Up 1.08% to $1.88 - IV Percentile
- Acrivon Therapeutics chief legal officer sells $585 in stock
- Mary Miller Executes Automatic Sale of 294 Shares at $1.99 for RSU Tax Withholding at Acrivon Therapeutics
- Acrivon Therapeutics (ACRV) Stock Analysis Report | Financials & Insights
Headlines from the last 30 days, linking to the original publishers. See all market news →